PL211693B1 - Gen Streptomyces Avermitilis kierujący stosunkiem awermektyn B2:B1 - Google Patents

Gen Streptomyces Avermitilis kierujący stosunkiem awermektyn B2:B1

Info

Publication number
PL211693B1
PL211693B1 PL371320A PL37132003A PL211693B1 PL 211693 B1 PL211693 B1 PL 211693B1 PL 371320 A PL371320 A PL 371320A PL 37132003 A PL37132003 A PL 37132003A PL 211693 B1 PL211693 B1 PL 211693B1
Authority
PL
Poland
Prior art keywords
amino acid
avec
avermitilis
combination
acid substitutions
Prior art date
Application number
PL371320A
Other languages
English (en)
Polish (pl)
Other versions
PL371320A1 (en
Inventor
Kim Jonelle Stutzman-Engwall
Claes Eric Daniel Gustafsson
Anke Krebber
Sun Ai Raillard
Jeremy Stephen Minshull
Seran Kim
Yan Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL371320A1 publication Critical patent/PL371320A1/xx
Publication of PL211693B1 publication Critical patent/PL211693B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • C12P19/60Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C12P19/623Avermectin; Milbemycin; Ivermectin; C-076

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
PL371320A 2002-02-12 2003-01-31 Gen Streptomyces Avermitilis kierujący stosunkiem awermektyn B2:B1 PL211693B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35622202P 2002-02-12 2002-02-12

Publications (2)

Publication Number Publication Date
PL371320A1 PL371320A1 (en) 2005-06-13
PL211693B1 true PL211693B1 (pl) 2012-06-29

Family

ID=27734621

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371320A PL211693B1 (pl) 2002-02-12 2003-01-31 Gen Streptomyces Avermitilis kierujący stosunkiem awermektyn B2:B1

Country Status (25)

Country Link
US (2) US7388085B2 (enExample)
EP (2) EP2050815B1 (enExample)
JP (1) JP2005517406A (enExample)
KR (1) KR100718378B1 (enExample)
CN (2) CN1630712B (enExample)
AR (1) AR038405A1 (enExample)
AT (2) ATE530645T1 (enExample)
AU (1) AU2003245052B2 (enExample)
BR (1) BRPI0307620B8 (enExample)
CA (1) CA2475214C (enExample)
CY (2) CY1110454T1 (enExample)
DE (1) DE60326824D1 (enExample)
DK (2) DK1476539T3 (enExample)
ES (2) ES2373629T3 (enExample)
IL (3) IL162866A0 (enExample)
ME (1) ME00472B (enExample)
MX (1) MXPA04007777A (enExample)
PL (1) PL211693B1 (enExample)
PT (2) PT1476539E (enExample)
RS (1) RS50813B (enExample)
RU (1) RU2293117C2 (enExample)
SI (2) SI1476539T1 (enExample)
TW (1) TWI341330B (enExample)
WO (1) WO2003068955A2 (enExample)
ZA (1) ZA200405345B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100718378B1 (ko) * 2002-02-12 2007-05-14 화이자 프로덕츠 인코포레이티드 B2:b1 아베르멕틴의 비를 제어하는 스트렙토마이세스아베르미틸리스 유전자
CN102241750B (zh) * 2010-05-14 2014-05-28 中国科学院微生物研究所 一种生产阿维菌素的基因工程方法及其专用菌株
CN102093997B (zh) * 2010-12-01 2013-03-13 中国科学院上海有机化学研究所 一种改造除虫链霉菌产生多拉菌素的方法
CN109576196B (zh) * 2019-01-25 2022-01-04 北大方正集团有限公司 一种生产多拉菌素的发酵培养基及多拉菌素的生产方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4429042A (en) 1978-09-08 1984-01-31 Merck & Co., Inc. Strain of Streptomyces for producing antiparasitic compounds
IN167980B (enExample) 1987-01-23 1991-01-19 Pfizer
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
KR100186946B1 (ko) * 1993-10-05 1999-04-01 알렌 제이.스피겔 도라멕틴의 구충활성 중간체 및 도라멕틴의 제조방법
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
HUP0100784A3 (en) * 1998-02-13 2004-10-28 Pfizer Prod Inc Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
US6248579B1 (en) * 1998-02-13 2001-06-19 Pfizer Inc Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
RU2156301C2 (ru) * 1998-06-09 2000-09-20 Мосин Владимир Александрович Штамм актиномицета streptomyces avermitilis ссм 4697 - продуцент авермектинов
US6197591B1 (en) 1998-09-14 2001-03-06 Pfizer Inc. Streptomyces avermitilis regulatory genes for increased avermectin production
EP1200606B1 (en) * 1999-08-12 2006-10-04 Pfizer Products Inc. Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
CA2381882C (en) 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
KR100718378B1 (ko) 2002-02-12 2007-05-14 화이자 프로덕츠 인코포레이티드 B2:b1 아베르멕틴의 비를 제어하는 스트렙토마이세스아베르미틸리스 유전자

Also Published As

Publication number Publication date
ES2321827T3 (es) 2009-06-12
KR100718378B1 (ko) 2007-05-14
EP1476539A2 (en) 2004-11-17
TWI341330B (en) 2011-05-01
US20030166165A1 (en) 2003-09-04
IL162866A (en) 2009-11-18
ATE426659T1 (de) 2009-04-15
AR038405A1 (es) 2005-01-12
AU2003245052A1 (en) 2003-09-04
CA2475214C (en) 2012-07-31
US7388085B2 (en) 2008-06-17
HK1074644A1 (en) 2005-11-18
RU2293117C2 (ru) 2007-02-10
EP2050815A1 (en) 2009-04-22
TW200303918A (en) 2003-09-16
IL192371A0 (en) 2008-12-29
WO2003068955A2 (en) 2003-08-21
DE60326824D1 (de) 2009-05-07
EP2050815B1 (en) 2011-10-26
PL371320A1 (en) 2005-06-13
US20090017508A1 (en) 2009-01-15
RS70004A (sr) 2006-10-27
RU2004124521A (ru) 2005-04-10
CN102392028B (zh) 2013-08-14
IL162866A0 (en) 2005-11-20
HK1168383A1 (en) 2012-12-28
ME00472B (me) 2011-10-10
EP1476539B1 (en) 2009-03-25
ATE530645T1 (de) 2011-11-15
MXPA04007777A (es) 2004-10-15
ZA200405345B (en) 2005-06-14
ES2373629T3 (es) 2012-02-07
CN1630712A (zh) 2005-06-22
DK2050815T3 (da) 2011-12-12
DK1476539T3 (da) 2009-05-11
WO2003068955A3 (en) 2003-11-13
CN102392028A (zh) 2012-03-28
CN1630712B (zh) 2011-09-28
BRPI0307620B8 (pt) 2016-09-13
CY1110454T1 (el) 2015-04-29
SI1476539T1 (sl) 2009-06-30
IL192371A (en) 2010-11-30
BRPI0307620B1 (pt) 2015-08-11
CA2475214A1 (en) 2003-08-21
AU2003245052B2 (en) 2008-07-31
BR0307620A (pt) 2004-12-07
RS50813B (sr) 2010-08-31
US8008078B2 (en) 2011-08-30
JP2005517406A (ja) 2005-06-16
KR20040081199A (ko) 2004-09-20
SI2050815T1 (sl) 2012-01-31
PT2050815E (pt) 2012-01-02
PT1476539E (pt) 2009-04-09
CY1112491T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
US8008078B2 (en) Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
JP3688640B2 (ja) B2:B1アベルメクチン比率を支配するStreptomycesavermitilis遺伝子
PL194270B1 (pl) Wyizolowana cząsteczka polinukleotydowa, cząsteczka oligonukleotydowa, zrekombinowany wektor, komórka gospodarza, wyizolowany produkt genu AveC S. avermitilis, wyizolowany produkt homologu genu AveC S. hygroscopicus, sposób wytwarzania zrekombinowanego produktu genu AveC, sposób wytwarzania zrekombinowanego produktu homologu genu AveC, cząsteczka polinukleotydowa, wektor do zastępowania genu, sposób identyfikowania mutacji otwartej ramki odczytuAveC, sposób wytwarzania nowych szczepów S. avermitilis, szczep S. avermitilis i sposób wytwarzaniaawermektyn
KR100489856B1 (ko) B2:b1 아베르멕틴의 비율을 제어하는 스트렙토마이세스아베르미틸리스 유전자
HK1168383B (en) Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
MXPA00007915A (en) I(streptomyces avermitilis) gene directing the ratio of b2:b1 avermectins
HK1074644B (en) Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins